There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for Bioventus Inc. (BVS) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.055, or 2.89%, to $1.96. The Bioventus Inc. has recorded 2,182 volume in the after hours trading session. The stock was recently discussed on Yahoo Finance as it revealed that Bioventus Enters into Settlement Agreement to Preserve Maximum Optionality – Up To $350mm of Potential Liability Reduction and a Release of Future Claims related to the CartiHeal Acquisition.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
This NASDAQ-listed company operates within the Medical Devices industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $1.90 and fluctuated between $2.2850 as its day high and $1.9000 as its day low. The current market capitalization of Bioventus Inc. is $160.44M. A total of 0.56 million shares were traded on the day, compared to an average of 1.29M shares.
Insider trades can also provide insight into a stock’s future direction. During the recent three months, BVS has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 12 BUYs and 3 SELLs from insiders. Insiders purchased 281,654 shares during that period but sold 114,976.
In the most recent transaction, Nosenzo John sold 65,963 shares of BVS for 11.12 per share on Apr 04. After the transaction, the Chief Commercial Officer now owns 83,932 company shares. In a previous transaction on Apr 04, Pavesio Alessandra sold 32,997 shares at 11.17 per share. BVS shares that SVP & Chief Science Officer owns now total 148,309.
Among the insiders who sold shares, D’Adamio Anthony disposed of 16,016 shares on Apr 04 at a per-share price of $11.19. This resulted in the SVP & General Counsel holding 40,132 shares of BVS after the transaction.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for BVS in the last 3 months, the mean price target is $6.50 with high estimates of $10.00 and low estimates of $3.00. In terms of 52-week highs and lows, BVS has a high of $15.10 and a low of $1.42.
As of this writing, BVS has an earnings estimate of $0.05 per share for the current quarter. EPS was calculated based on a consensus of 4 estimates, with a high estimate of $0.07 per share and a lower estimate of $0.03. The company reported an EPS of $0.1 in the last quarter, which was -37.50% lower than expectations of $0.16.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 3 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BVS is Buy with a score of 2.33. A total of 0 analysts rated the stock as Buy while 0 rated it as Overweight while 2 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 1 thought it should be Sold.